OrthoPediatrics reports Q3 adjusted EPS (13c), consensus (22c)

Reports Q3 revenue $39.97M, consensus $40.37M. David Bailey, president and CEO of OrthoPediatrics, commented, “In the third quarter our commercial and operational execution drove continued revenue and profitability growth trends for the business. We expect these positive trends to continue into next year supported by the combination of our strong balance sheet and recent product portfolio expansion, ApiFix, Orthex and the specialty bracing business, that are producing higher returns on invested capital while requiring reduced set deployments to drive profitable revenue growth.”